Assessment of the Efficacy of E. Coli 5C in the Management of Post-Colonoscopy Symptoms
NCT07931365, Not applicable, Not yet recruiting, Liaquat University of Medical & Health Sciences
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Assessment of the Efficacy of E. Coli 5C in the Management of Post-Colonoscopy Symptoms | ClinicalTrials.gov |
| NCT number | NCT07931365 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 160 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Liaquat University of Medical & Health Sciences | ClinicalTrials.gov |
| Conditions | Post-Colonoscopy Gastrointestinal Symptoms | ClinicalTrials.gov |
| Interventions | Colipral®, Placebo | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Gastrointestinal Symptom Rating Scale (GSRS) total score at Day 14 | Baseline to Day 14 after colonoscopy | Between-group difference in change in gastrointestinal symptom severity from baseline to Day 14 after colonoscopy, assessed using the Gastrointestinal Symptom Rating Scale (GSRS). | ClinicalTrials.gov |
| Secondary | Change in abdominal pain intensity score | 48 hours, Day 7, and Day 14 after colonoscopy | Between-group difference in abdominal pain intensity assessed using a Numerical Rating Scale (NRS, 0-10), with higher scores indicating greater symptom intensity, at 48 hours, Day 7, and Day 14 after colonoscopy. | ClinicalTrials.gov |
| Secondary | Change in abdominal bloating intensity score | 48 hours, Day 7, and Day 14 after colonoscopy | Between-group difference in abdominal bloating intensity assessed using a Numerical Rating Scale (NRS, 0-10), with higher scores indicating greater symptom intensity, at 48 hours, Day 7, and Day 14 after colonoscopy. | ClinicalTrials.gov |
| Secondary | Change in flatulence intensity score | 48 hours, Day 7, and Day 14 after colonoscopy | Between-group difference in flatulence intensity assessed using a Numerical Rating Scale (NRS, 0-10), with higher scores indicating greater symptom intensity, at 48 hours, Day 7, and Day 14 after colonoscopy. | ClinicalTrials.gov |
| Secondary | Change in stool consistency assessed by Bristol Stool Form Scale | 48 hours, Day 7, and Day 14 after colonoscopy | Between-group difference in stool consistency assessed using the Bristol Stool Form Scale at 48 hours, Day 7, and Day 14 after colonoscopy. | ClinicalTrials.gov |
| Secondary | Change in frequency of bowel movements | 48 hours, Day 7, and Day 14 after colonoscopy | Between-group difference in the mean number of daily bowel movements recorded at 48 hours, Day 7, and Day 14 after colonoscopy. | ClinicalTrials.gov |
| Secondary | Global Assessment of Change of Gastrointestinal Symptoms (PGIC) score at Day 7 and Day 14 | Day 7 and Day 14 after colonoscopy | Between-group difference in the Global Assessment of Change of Gastrointestinal Symptoms at Day 7 and Day 14, measured using the Patient Global Impression of Change (PGIC), a 7-category ordinal scale ranging from "Very much worse" to "Very much improved". | ClinicalTrials.gov |
| Secondary | Proportion of participants with clinically relevant improvement in gastrointestinal symptoms | Day 7 and Day 14 after colonoscopy | Proportion of participants with clinically relevant improvement in gastrointestinal symptoms, defined as a PGIC response of "Improved", assessed at Day 7 and Day 14 after colonoscopy. | ClinicalTrials.gov |
| Secondary | Use of rescue medication for gastrointestinal symptoms | Within 14 days after colonoscopy | Proportion of participants who used concomitant or rescue medication for control of gastrointestinal symptoms within 14 days after colonoscopy. Type of drug, days of intake, and dose will also be recorded. | ClinicalTrials.gov |
| Secondary | Frequency of adverse events | Within 14 days after colonoscopy | Frequency and type of adverse events reported within 14 days after colonoscopy, including suspected allergic symptoms, nausea, vomiting, and other clinically relevant events. | ClinicalTrials.gov |
| Secondary | Treatment tolerability score | Day 14 after colonoscopy | Treatment tolerability assessed using a numerical score from 0 to 10 during the 14-day post-colonoscopy period. | ClinicalTrials.gov |
| Secondary | Adherence to treatment | Within 14 days after colonoscopy | Adherence to study treatment, expressed as the percentage of doses taken compared with those expected during the 14-day observation period. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)